(Q43872639)

27 November 2017

title

In vitro susceptibility of recent clinical isolates of pneumococci to the investigational cephalosporin cefditoren (English)

1 reference

27 November 2017

5

Clyde Thornsberry

1 reference

27 November 2017

6

Daniel F Sahm

1 reference

27 November 2017

James A Karlowsky

1

1 reference

27 November 2017

Mark E Jones

series ordinal

2

1 reference

27 November 2017

Deborah C Draghi

series ordinal

3

1 reference

27 November 2017

Ian A Critchley

series ordinal

4

1 reference

27 November 2017

publication date

1 January 2002

1 reference

Diagnostic Microbiology and Infectious Disease

27 November 2017

published in

1 reference

27 November 2017

volume

42

1 reference

27 November 2017

issue

1

1 reference

27 November 2017

page(s)

59-64

1 reference

Treatment of penicillin-resistant pneumococcal bacteremia in neutropenic patients with cancer.

27 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900304-2

7 January 2021

Molecular characterization of penicillin-resistant Streptococcus pneumoniae isolates causing respiratory disease in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900304-2

7 January 2021

Clonal relationships among high-level penicillin-resistant Streptococcus pneumoniae in the United States.

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900304-2

7 January 2021

Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999--2000, including a comparison of resistance rates since 1994--1995.

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900304-2

7 January 2021

Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 results from the SENTRY antimicrobial surveillance program

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900304-2

7 January 2021

Susceptibility of Streptococcus pneumoniae and Haemophilus influenzae to cefditoren, and provisional interpretive criteria.

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900304-2

7 January 2021

Prevalence of human immunodeficiency virus infection, mortality rate, and serogroup distribution among patients with pneumococcal bacteremia at Denver General Hospital, 1984-1994.

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900304-2

7 January 2021

Antimicrobial activity and in vitro susceptibility test development for cefditoren against Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus species

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900304-2

7 January 2021

Benchmarking the in vitro activities of moxifloxacin and comparator agents against recent respiratory isolates from 377 medical centers throughout the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900304-2

7 January 2021

In vitro evaluation of a novel orally administered cephalosporin (Cefditoren) tested against 1249 recent clinical isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae.

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900304-2

7 January 2021

Cefditoren activity against nearly 1000 non-fastidious bacterial isolates and the development of in vitro susceptibility test methods.

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900304-2

7 January 2021

Comparison of agar dilution, microdilution, E-test, and disk diffusion methods for testing activity of cefditoren against Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900304-2

7 January 2021

Pneumococcal resistance to antibiotics

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900304-2

7 January 2021

Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain.

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900304-2

7 January 2021

Usefulness of betalactam therapy for community-acquired pneumonia in the era of drug-resistant Streptococcus pneumoniae: a randomized study of amoxicillin-clavulanate and ceftriaxone.

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900304-2

7 January 2021

Identification of clinical risk factors for nosocomial pneumococcal bacteremia

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900304-2

7 January 2021

Time-kill studies on susceptibility of nine penicillin-susceptible and -resistant pneumococci to cefditoren compared with nine other beta-lactams

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900304-2

7 January 2021

Activities of RPR 106972 (a new oral streptogramin), cefditoren (a new oral cephalosporin), two new oxazolidinones (U-100592 and U-100766), and other oral and parenteral agents against 203 penicillin-susceptible and -resistant pneumococci.

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900304-2

7 January 2021

Antimicrobial resistance of Streptococcus pneumoniae in the United States, 1979-1987. The Pneumococcal Surveillance Working Group

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900304-2

7 January 2021

Resistance surveillance of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated in the United States, 1997-1998.

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900304-2

7 January 2021

Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States in 1996-1997 respiratory season. The Laboratory Investigator Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900304-2

7 January 2021

10.1016/S0732-8893(01)00304-2

Identifiers

DOI

1 reference

27 November 2017

1 reference